GlassScriptPhysician profile
Robert A Humphreys
NPI 1295744134
$9,810.51
in general payments reported to CMS, 2019-2025
33 companies · $1,296 in 2025
The $1,296 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,189 · 2020: $366 · 2021: $1,546 · 2022: $1,267 · 2023: $1,609 · 2024: $1,538 · 2025: $1,296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,442.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,442.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,382.77 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,511.94 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $850.19 | 2019-2025 | Jardiance, Ofev |
| Lilly USA, LLC | $838.12 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $545.51 | 2021-2025 | |
| Abbvie INC. | $543.58 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $440.01 | 2019-2025 | Belsomra, Lagevrio, Capvaxive |
| Pfizer INC. | $377.25 | 2019-2025 | |
| Amarin Pharma, INC. | $297.11 | 2019-2022 | |
| Astellas Pharma US INC | $202.06 | 2019-2021 | |
| Amgen INC. | $199.30 | 2019-2025 | Otezla, Repatha, Repatha |
| Allergan, INC. | $196.60 | 2019-2020 | |
| Abbott Laboratories | $178.14 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $174.51 | 2019-2021 | |
| Glaxosmithkline, LLC. | $157.61 | 2019-2025 | Arexvy, Penmenvy, Bexsero |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $96.85 | 2019-2023 | |
| Daiichi Sankyo INC. | $92.43 | 2024-2025 | Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $90.93 | 2021-2022 | |
| Genentech USA, INC. | $85.06 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.77 | 2019-2023 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $76.95 | 2024-2025 | Voquezna |
| Seqirus USA INC | $62.56 | 2025 | Flucelvax, Fluad |
| Sumitomo Pharma America, INC. | $61.56 | 2023-2024 | Gemtesa |
| Idorsia Pharmaceuticals US INC | $40.52 | 2022-2023 | Quviviq |
| Xeris Pharmaceuticals, INC. | $40.31 | 2022-2025 | Gvoke Hypopen |
| Biohaven Pharmaceutical Holding Company LTD. | $37.84 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $31.16 | 2021 | |
| Acadia Pharmaceuticals INC | $30.30 | 2025 | Nuplazid |
| Shire North American Group INC | $26.45 | 2019 | |
| Eisai INC. | $19.64 | 2021 | |
| Nalpropion Pharmaceuticals LLC | $14.87 | 2019 | |
| Celgene Corporation | $12.56 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Humphreys listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.